InspireMD (NYSE:NSPR) versus InfuSystem (NYSE:INFU) Head-To-Head Contrast

InfuSystem (NYSE:INFU) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares InfuSystem and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
InspireMD	-413.96%	-69.42%	-57.68%

Analyst Ratings

This is a breakdown of recent ratings and target prices for InfuSystem and InspireMD, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	0	0	3	4.00
InspireMD	0	0	2	0	3.00

InfuSystem currently has a consensus price target of $12.50, suggesting a potential upside of 30.62%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 89.08%. Given InspireMD’s higher probable upside, analysts plainly believe InspireMD is more favorable than InfuSystem.

Risk & Volatility

InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by insiders. Comparatively, 34.1% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares InfuSystem and InspireMD”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$139.89 million	1.40	$870,000.00	$0.23	41.61
InspireMD	$7.07 million	14.05	-$19.92 million	($0.83)	-2.87

InfuSystem has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Summary

InfuSystem beats InspireMD on 11 of the 15 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.